Spermosens AB (publ)YEAR-END REPORT JANUARY – DECEMBER 2025

Spermosens reported zero net sales for 2025 and an operating loss of SEK -9.2m (2024: -9.16m), with EPS of SEK -0.004; cash and cash equivalents rose to SEK 6.84m from SEK 0.66m and equity increased to SEK 32.41m. The company secured strategic investment in Q1 2025, received multiple patent grants (Canada, Mexico, Israel, China and previously other major markets), announced positive clinical results linking JUNO binding to fertilization rates, signed post-period MoUs with Sapyen and RSI for commercialization in key markets, and expects its Generation 3 diagnostic system to be completed and validated in H1 2026—catalysts that materially de-risk commercialization despite ongoing operating losses.

Analysis

Market structure: Spermosens’s validated JUNO-binding assay creates a niche winner set — specialists selling male-fertility functional diagnostics, IVF clinics that can improve fertilization rates, and large lab-platform suppliers that integrate new assays. Patents granted in Europe, North America, China, Japan and Australia materially reduce IP risk and increase licensing leverage; expect licensing/royalty economics rather than heavy capital equipment sales, putting pricing power with licensors and major diagnostic partners. The immediate demand signal is unmet: male factors contribute to ~50% of infertility cases, implying a conservative service TAM of several hundred million USD in developed markets if clinics adopt JUNO-Checked as a routine pre‑IVF test.

Risk assessment: Key tail risks are partner deals failing (commercialization dependency), clinical non‑replication in larger cohorts, and reimbursement/regulatory setbacks (CE/FDA timelines). Financially, dilution is severe (shares jumped from ~283M to 3.17B) and cash at year‑end SEK 6.8M — runway likely measured in months without partner milestone payments; watch for further raises. Time windows: market moves in days on deal news, meaningful commercial validation or FDA pre‑submission in 3–12 months, platform completion and scale in H1 2026.

Trade implications: For risk‑seeking allocations, a small, conditional long in Spermosens is justified (see decisions) while hedging exposure to commercialization execution risk by buying 6–12 month call spreads on large diagnostics suppliers (e.g., DHR, TMO) that would benefit from assay adoption. Pair trades: long Spermosens, short a Nordic small‑cap medtech basket to neutralize regional small‑cap risk. Options: use calendar/call spreads to cap premium given milestone timing (6–12 months).

Contrarian angles: Consensus may overvalue patent grants as equivalent to commercial success — missing dependencies: partner distribution, lab workflow integration, reimbursement codes and manufacturing scale. Reaction is underdone if a Tier‑1 partner signs a license (value jump via royalty upside) and overdone if markets price in immediate revenues despite zero sales. Historical parallels: technical winners in diagnostics (e.g., specific biomarker assays) often saw binary outcomes—either rapid adoption via a major partner or long stagnation; plan for binary payoffs and asymmetric sizing.

Key Decisions for Investors

• Establish a speculative 1–2% long position in Spermosens AB (small‑cap Nordic diagnostics) now; scale to 4–5% only if within 6 months a binding commercial license is announced with RSI Technology Group or Sapyen, or a peer‑reviewed replication shows >=10 percentage‑point improvement in predicted fertilization rates. Set stop‑loss: reduce to 0% if no license, no external funding, or cash < SEK 3M within 9 months.
• Buy 1–2% allocation to large diagnostics/platform suppliers to play downstream adoption: preferentially Danaher (DHR) or Thermo Fisher (TMO). Implement 6–12 month call spreads ~5–10% OTM (buy 12‑month call, sell a higher strike) to limit premium; increase exposure by 1% if a Spermosens commercial partner deal is announced.
• Implement a pair trade to hedge execution risk: long Spermosens 1–2% vs short 1% notional of a Nordic small‑cap medtech ETF or basket (to be specified by trading desk) to neutralize regional/small‑cap volatility. Close or flip within 6–9 months upon licensing/regulatory catalysts.
• Do not initiate larger exposure until two catalysts occur: (A) signed commercial license with revenue share or milestone payments, or (B) regulatory clearance roadmap (CE/FDA pre‑submission) confirmed. If either occurs, reallocate up to 3–5% total portfolio exposure within 30 days of announcement.